Search Drug Information, Interactions, Images, Dosage & Side Effects

Novel device delivers improvements for BPH symptoms

31 Mar 2023

Antibiotics linked to higher EAC risk

31 Mar 2023

Tenofovir disoproxil fumarate as good as entecavir for patients with HBV-related liver cancer

30 Mar 2023

Chemo-induced nausea? Putting on some music may help, study suggests

30 Mar 2023

Young adults with SLE at higher risk of 30-day rehospitalization

30 Mar 2023

Ceftolozane/tazobactam on par with meropenem in children with complicated UTI

30 Mar 2023

Fructose from sweetened drinks tied to harmful levels of cardiometabolic biomarkers

30 Mar 2023

Remdesivir cuts mortality in COVID-19 patients requiring no or low-flow oxygen

30 Mar 2023

Indapamide shows low incidence of severe hypokalaemia in patients with hypertension

30 Mar 2023

Low-concentration atropine eye drops may reduce myopia incidence in high-risk children

30 Mar 2023

EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute heart failure 21 Mar 2023;
Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.